Brief: Alligator Bioscience And Scandion Oncology Present Promising Preclinical Data

Alligator Bioscience AB

30/06/2021 07:40

June 30 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * ALLIGATOR BIOSCIENCE AB AND SCANDION ONCOLOGY A/S PRESENT
PROMISING PRECLINICAL DATA
    * PROMISING PRECLINICAL DATA FROM ONGOING COLLABORATION
EXPLORING
ANTI-TUMOR EFFECTS ON DRUG RESISTANT CANCER
    * COMBINATION OF MITAZALIMAB AND FOLFIRINOX DEMONSTRATES A
STRONG
ANTI-TUMOR RESPONSE IN FOLFIRINOX RESISTANT CANCER CELLS
    * CURRENT DATA INDICATE THAT ANTI-TUMOR EFFECT OF SCO-101,
MITAZALIMAB AND FOLFIRINOX IS EVEN MORE POTENT THAN MITAZALIMAB
AND FOLFIRINOX
    * STUDIES ARE STILL ONGOING AND FURTHER MONITORED FOR
ANTI-TUMOR
EFFECTS AND SURVIVAL
    * DATA FURTHER VALIDATE POTENTIAL OF MITAZALIMAB IN
COMBINATION
WITH STANDARD OF CARE CHEMOTHERAPY SUCH AS FOLFIRINOX

Source text for Eikon:  ID:nWkr9nfQ94 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))